MTOR and prostate cancer: In earlier studies, using the same large prostate cancer cohort we had described other very strong and often independent prognostic features such as for example ß3-tubulin [20], CD57 [21], DAXX [22], HOXB13 [23], KPNA2 [24], RBM3 [25], mTOR [26], p62 [27], and TYMS [28], that might also be worth testing in multiparametric prognostic kits.